Pfizer's Xtandi delays prostate cancer spread in early stage disease

(Reuters) – Use of Xtandi in early stage prostate cancer on top of standard hormone therapy reduced the risk of disease spreading or death by 71 percent compared with hormone therapy alone, study results that could lead to significantly increased sales of the Pfizer Inc and Astellas Pharma Inc medicine.

Source: Reuters Medical News

Leave a Reply

Your email address will not be published. Required fields are marked *